Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.

Lang DM.

Ann Allergy Asthma Immunol. 2014 Apr;112(4):276-9. doi: 10.1016/j.anai.2014.01.019. Epub 2014 Feb 28. No abstract available.

PMID:
24589165
2.

A patient with steroids and antihistaminic drug allergy and newly occurred chronic urticaria angioedema: what about omalizumab?

Kutlu A, Karabacak E, Aydin E, Ozturk S, Bozkurt B.

Hum Exp Toxicol. 2014 Aug;33(8):882-5. doi: 10.1177/0960327113510539. Epub 2013 Nov 7.

PMID:
24203455
3.

Omalizumab for the treatment of chronic urticaria.

Zuberbier T, Maurer M.

Expert Rev Clin Immunol. 2015 Feb;11(2):171-80. doi: 10.1586/1744666X.2015.993971. Epub 2015 Jan 7. Review.

PMID:
25566680
4.

Omalizumab in the treatment of chronic urticaria.

Francés L, Leiva-Salinas M, Silvestre JF.

Actas Dermosifiliogr. 2014 Jan-Feb;105(1):45-52. doi: 10.1016/j.ad.2013.06.002. Epub 2013 Aug 12. Review. English, Spanish.

PMID:
23938072
5.

Omalizumab for chronic urticaria.

Casale TB.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):118-9. doi: 10.1016/j.jaip.2013.11.004. No abstract available.

PMID:
24565785
6.

Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.

Lang DM.

Drugs Today (Barc). 2015 Jun;51(6):367-74. doi: 10.1358/dot.2015.51.6.2333219. Review.

PMID:
26261850
7.

Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.

Rodríguez-Trabado A, Fernández Pereira LM, Romero-Chala S, García-Trujillo JA, Cámara Hijón C.

Allergol Immunopathol (Madr). 2012 Nov-Dec;40(6):390-2. doi: 10.1016/j.aller.2011.09.009. Epub 2011 Dec 15. No abstract available.

PMID:
22178123
8.

[Argentine guidelines for urticaria and angioedema].

Máspero J, Cabrera H, Ardusso L, De Gennaro M, Fernández Bussy R, Galimany J, Galimberti D, Label M, La Forgia M, Medina I, Neffen H, Troielli P; Asociación Argentina de Alergia e Inmunología Clínica (AAAeIC); Sociedad Argentina de Dermatología.

Medicina (B Aires). 2014;74 Suppl 1:1-53. Spanish.

9.

The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.

Mauro M, Incorvaia C, Formigoni C, Elia R, Russello M, Pellegrino D.

Panminerva Med. 2012 Dec;54(4):305-12. Review.

PMID:
23123583
10.

Omalizumab in chronic urticaria.

Metz M, Maurer M.

Curr Opin Allergy Clin Immunol. 2012 Aug;12(4):406-11. doi: 10.1097/ACI.0b013e328355365a. Review.

PMID:
22766620
11.

Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema.

Pressler A, Grosber M, Halle M, Ring J, Brockow K.

Clin Exp Dermatol. 2013 Mar;38(2):151-3. doi: 10.1111/j.1365-2230.2012.04430.x. Epub 2012 Jun 25.

PMID:
22731986
12.

Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.

Metz M, Ohanyan T, Church MK, Maurer M.

J Dermatol Sci. 2014 Jan;73(1):57-62. doi: 10.1016/j.jdermsci.2013.08.011. Epub 2013 Sep 3.

PMID:
24060603
13.

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.

Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M.

J Allergy Clin Immunol. 2015 Feb;135(2):337-42. doi: 10.1016/j.jaci.2014.04.036. Epub 2014 Jun 17. Review.

PMID:
24948369
14.

Extraordinary response to omalizumab in a child with severe chronic urticaria.

Asero R, Casalone R, Iemoli E.

Eur Ann Allergy Clin Immunol. 2014 Jan;46(1):41-2.

PMID:
24702874
15.

Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.

Altman K, Chang C.

Clin Rev Allergy Immunol. 2013 Aug;45(1):47-62. doi: 10.1007/s12016-012-8326-y. Review.

PMID:
22674016
16.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal.

Durack A, Matin RN.

Br J Dermatol. 2014 Jul;171(1):10-3. doi: 10.1111/bjd.13073. No abstract available.

PMID:
25066288
17.

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.

Kai AC, Flohr C, Grattan CE.

Clin Exp Dermatol. 2014 Jul;39(5):651-2. doi: 10.1111/ced.12320. Epub 2014 Apr 23. No abstract available.

PMID:
24758481
18.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.

J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2.

PMID:
21636116
19.

The potential role of omalizumab in the treatment of chronic urticaria.

Stitt JM, Dreskin SC.

Immunotherapy. 2014;6(6):691-7. doi: 10.2217/imt.14.31.

PMID:
25186602
20.

Omalizumab beyond asthma.

Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R.

Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. Epub 2012 Jan 20. Review.

PMID:
22264640

Supplemental Content

Support Center